HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

Three cell & gene therapy groups - ISCT, ARM & ASGCT - jointly call for 10-year global ban on human germline gene editing, ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

Cytokinetics's aficamten outperforms metoprolol in Phase 3 heart disease trial, but FDA approval delayed to December due to ...

Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap Therapeutics, Remedy Plan, Lexeo, Karyopharm, Tango Therapeutics and Humacyte.

White House drug pricing plan faces skepticism as experts question feasibility of Trump's executive order to align US prices ...

To­day on Post Hoc Live, Drew Arm­strong is joined by Nick Ship­ley, the for­mer top lob­by­ist for the biotech in­dus­try, ...